Studies have shown that LSD1 forms nuclear complexes with Eomes of CD8+ CTLs from immunotherapy-resistant melanoma and breast cancer patients, ultimately mediating dysfunction of CD8+ CTLs [146, 147], and targeting the phosphorylation of the LSD1 pathway can increase the cytotoxicity of CD8+ CTLs [147]. Here, CD8A is linked to melanoma.